View                 Download                 XML
Authors *Shailendra Shekhar Jadiya
Description Now it&rsquo;s proved- Monoclonal antibodies are very important therapeutic tools for cancer. Today, more than 314 Mabs products are in clinical study worldwide. The recent clinical success of anticancer Monoclonal antibodies like Catumaxomab, Brentuximab, Denosumab, Ipilimumab, Tocilizumab are widely used and these are proving of success rate about Monoclonal antibodies for different cancer treatment. Monoclonal antibody therapy has emerged as an important therapeutic modality for cancer. In 1975, Kohler and Milstein discovered how to prepare hybridomas: a new cell type, resulting from the fusion of B-lymphocytes (immune cells of mouse) with a myeloma (cancer) cell. Hybridomas are cells that have been engineered to produce a desired monoclonal antibody in large amounts. Monoclonal antibodies are targeted at specific receptors on cancer cells. Currently, there are more than 20 new monoclonal antibodies- including murine, chimeric, humanized and human that have won FDA approval, including those aimed at transplant rejection, auto-immune disorders, leukemia, colorectal cancer, breast cancer, non-Hodgkin lymphoma, certain viral infections, and macular degeneration. Past, present &amp; future planning about Mabs are discussed. <br />